Novo Says Still Some Uncertainty on Tresiba Costs

Oct. 31 (Bloomberg) -- Novo Nordisk A/S Chief Financial Officer Jesper Brandgaard talks about the company's third-quarter profit reported today, sales forecast and the launch of its new diabetes treatment, Tresiba. He speaks from Bagsvaerd, Denmark, with Caroline Hyde on Bloomberg Television's "The Pulse." (Source: Bloomberg)
How Long Can the 'Pain Trade' Last?
22:16 - Savita Subramanian, BofA Merrill Lynch's head of U.S. equity and quantitative strategy, discusses the outlook for U.S. stocks with Bloomberg's Scarlet Fu, Alix Steel and Joe Weisenthal on "What'd You Miss?" (Source: Bloomberg)
  • Fourth-Quarter Earnings Themes: Oil, Dollar and China
  • What's Ruining the Fed's Rate Hike Plan?
  • Deep Dive: Can the S&P 500 Break Through?